Witnessing the stock’s movement on the chart, on Wednesday, Mereo Biopharma Group Plc ADR (NASDAQ: MREO) had a quiet start as it plunged -4.09% to $2.58, before settling in for the price of $2.69 at the close. Taking a more long-term approach, MREO posted a 52-week range of $0.92-$4.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -20.00%. Meanwhile, its Annual Earning per share during the time was 41.78%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 68.75%. This publicly-traded company’s shares outstanding now amounts to $140.06 million, simultaneously with a float of $140.06 million. The organization now has a market capitalization sitting at $361.35 million. At the time of writing, stock’s 50-day Moving Average stood at $3.39, while the 200-day Moving Average is $2.25.
Mereo Biopharma Group Plc ADR (MREO) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Mereo Biopharma Group Plc ADR’s current insider ownership accounts for 0.00%, in contrast to 61.40% institutional ownership.
Mereo Biopharma Group Plc ADR (MREO) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.58 per share during the current fiscal year.
Mereo Biopharma Group Plc ADR’s EPS increase for this current 12-month fiscal period is 68.75% and is forecasted to reach -0.04 in the upcoming year.
Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Trading Performance Indicators
Let’s observe the current performance indicators for Mereo Biopharma Group Plc ADR (MREO). It’s Quick Ratio in the last reported quarter now stands at 3.11. The Stock has managed to achieve an average true range (ATR) of 0.19. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 41.11.
In the same vein, MREO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.25, and analysts are predicting that it will be -0.04 at the market close of one year from today.
Technical Analysis of Mereo Biopharma Group Plc ADR (MREO)
Going through the that latest performance of [Mereo Biopharma Group Plc ADR, MREO]. Its last 5-days volume of 1.08 million was inferior to the volume of 1.64 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 8.93% While, its Average True Range was 0.18.
Raw Stochastic average of Mereo Biopharma Group Plc ADR (MREO) in the period of the previous 100 days is set at 28.80%, which indicates a major rise in contrast to 0.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 64.57% that was lower than 65.49% volatility it exhibited in the past 100-days period.
